The purpose of this study was to assess the effectiveness of azimilide, a class III antiarrhythmic drug, in reducing the frequency of symptomatic arrhythmia recurrences in patients with atrial fibrillation, atrial flutter or both. BACKGROUND Atrial fibrillation is an increasingly common disorder of the heart rhythm, and most patients with this problem are identified because they have symptoms associated with their arrhythmia. New antiarrhythmic therapies are needed to treat patients with this problem.
Atrial fibrillation (AF) is a disorder of the heart rhythm in which normal sinus rhythm is punctuated by periods of abnormal rhythm that is recognized by patients as the sudden onset of symptoms including palpitations, chest pain and dyspnea. The Cardiovascular Health Study, a cohort study that is following a population Ͼ65 years old, showed that the incidence of atrial fibrillation is increasing and that most patients are identified because they have symptoms when their rhythm is abnormal (1) . Current antiarrhythmic drugs are limited in their use by imperfect efficacy and uncertain safety. In addition, as the population ages, there will be an increased need for new, convenient antiarrhythmic drugs that reduce the frequency of symptomatic occurrences of atrial fibrillation. Azimilide is a novel class III antiarrhythmic drug that blocks both I Kr and I Ks channels and that has been developed for atrial fibrillation; the combined effect of I Kr and I Ks blockade may decrease the proarrhythmic potential of azimilide. Because clinical experience with azimilide is limited (2) , in this study azimilide doses of 50, 100 and 125 mg daily (QD) were evaluated to test the hypothesis that azimilide lengthened the symptomatic arrhythmia-free period for patients with AF, atrial flutter or both.
METHODS
Entry criteria. To be eligible, male or female patients with age Ն18 years were required to have a history of symptomatic AF, atrial flutter or both and to be candidates for antiarrhythmic therapy based on the judgment of the investigator enrolling them. Investigators were required to provide an electrocardiogram (ECG) showing AF or atrial flutter that had been recorded within 24 months of the date of randomization, and patients were required to be in sinus rhythm at the time of randomization. Important cardiovascular exclusions were angina at rest; symptoms of heart failure at rest; thoracic surgery, cardiac surgery or myocardial infarction within two months; a history of torsade de pointes or any other polymorphic ventricular tachycardia; resting heart rate Ͻ50 beats/min or QTc on an ECG recording in sinus rhythm Ͼ440. Other exclusion criteria were blood urea nitrogen Ͼ50 mg/dl or serum creatinine Ͼ2.0 mg/dl. Randomization and follow-up. A permuted block randomization scheme was used to assign equal numbers of patients to four treatment groups: placebo or azimilide 50 mg, 100 mg or 125 mg. The assigned treatment was given twice a day (BID) for three days (the loading period) and then the frequency was reduced to QD during the efficacy period for up to 180 days. If a patient had a symptomatic arrhythmia recurrence during the loading period and the arrhythmia was present at midnight of day 3, then the efficacy period was adjusted to begin at the first time the patient had documented resumption of sinus rhythm. If sinus rhythm was not restored (spontaneously or by pharmacologic or direct current cardioversion) by day 10, the patient was withdrawn from the trial.
When initiating randomized therapy, no titration was used and no dose adjustments were made for weight, gender, serum creatinine, associated diseases or concomitant medications. Treatment was initiated in both inpatients and outpatients. Symptomatic arrhythmia recurrence was documented using transtelephonic ECG monitoring. Electrocardiograms recorded during hospital stays or emergency department visits also were obtained; all ECGs from symptomatic arrhythmia recurrences were reviewed by an event committee that was blinded to the patient's treatment assignment and arrhythmia history. Transtelephonic ECG monitoring also was used every two weeks during follow-up to record an ECG when patients were asymptomatic. Patients completed follow-up by having a symptomatic recurrence of their arrhythmia documented by ECG or by finishing 180 days with no arrhythmia recurrence. Data analysis. The protocol explicitly specified primary, secondary and additional efficacy analyses. Statistical analyses were done using SAS/STAT (SAS Institute Inc., Cary, North Carolina). The primary outcome variable was the time to first symptomatic arrhythmia recurrence documented by an ECG consistent with AF, atrial flutter or paroxysmal supraventricular tachycardia (completion events). The Kaplan-Meier life-table method was used to display the outcome data and to estimate the median recurrence time for each group (3) . Differences between groups were compared with the log-rank test. The Cox proportional hazards model was used to calculate a hazard ratio (placebo:azimilide) for each comparison (3).
The protocol-specified primary efficacy analysis compared the placebo group with the combined 100 mg QD and 125 mg QD doses during the efficacy period (excluding the three-day loading period); this analysis used a two-sided log-rank test and alpha ϭ 0.05. Combining the 100 mg and 125 mg dose groups increased the statistical power of the primary data analysis compared with doing multiple analyses of individual doses. Additional protocol-specified efficacy analyses compared individual doses with placebo.
Because the primary efficacy analysis excluded symptomatic arrhythmia events that occurred during the loading period, all efficacy analyses were repeated using data from the loading period as well as the efficacy period (called day 1 analyses). These latter analyses, which were specified in the protocol, were planned to assess whether including the loading period, when blood azimilide concentrations should have been lower compared with the efficacy period, decreased the magnitude of the treatment effect.
A log-rank trend test was done across all doses to test for a dose response. A secondary efficacy analysis specified in the protocol compared heart rate during arrhythmia recurrences. Finally, asymptomatic arrhythmia occurrences were tabulated in the four treatment groups in an exploratory analysis.
Adverse events were counted for all randomized patients from day 1 and, therefore, included both the loading period and the efficacy period. Patients were required to withdraw for QTc Ͼ525. Adverse events were included in the safety analysis if they occurred within 30 days of patient withdrawal for any reason. Safety variables reported here are deaths, torsades de pointes, withdrawal for 12-lead ECG with QTc Ն525 and withdrawals for any other adverse event. The QTc was measured on day 4 from a 12-lead ECG and compared with the QTc measured on a baseline (pretreatment) ECG. Study chronology. The first patient was enrolled on September 4, 1996, and the last patient finished follow-up on October 6, 1997. The protocol was approved by an institutional review board for clinical investigations at each study site. One protocol amendment was filed to change the statistical analysis plan; this amendment was filed before the study data base was locked or unblinded.
RESULTS

Study population.
A total of 384 patients were recruited at 97 sites and randomized among the four treatments: 93 patients to placebo, 101 patients to azimilide 50 mg QD, 97 to 100 mg QD and 93 to 125 mg QD. Twenty-eight patients (5.3%) were in the hospital at the time they received their first dose of blinded therapy. Demographic and baseline cardiovascular characteristics were well balanced among the treatment groups (Table 1) as was the use of common concomitant medications (Table 2 ). Overall 76.8% of patients had some form of structural heart disease, which was defined as a diagnosis of coronary artery disease (with or without myocardial infarction), congestive heart failure, valvular heart disease, hypertension with cardiomyopathy,
Abbreviations and Acronyms
AF ϭ atrial fibrillation BID ϭ twice daily CI ϭ confidence interval ECG ϭ electrocardiogram QD ϭ daily hypertension with left ventricular hypertrophy, left atrial enlargement by echocardiogram or conduction system disease. Thirty-four percent had a history of treatment with direct current cardioversion before randomization.
About one-third of the patients had a history of multiple arrhythmias recorded by ECG before randomization. Only 61% of patients had just a history of AF while 7% had just atrial flutter. Seventeen percent had prior ECGs showing both AF and atrial flutter and 13% had prior ECGs showing AF or atrial flutter and another regular rhythm without evident atrioventricular dissociation that was typical for paroxysmal supraventricular tachycardia. Primary efficacy analysis. Among the 384 randomized patients, 367 entered the efficacy period in sinus rhythm after the end of the loading period. The primary efficacy analysis compared placebo patients (n ϭ 87) who entered the efficacy period with a combined group of patients who received azimilide 100 mg QD and patients who received azimilide 125 mg QD (n ϭ 181). The log-rank test p value for this comparison was 0.005 (chi-square 7.96), and the hazard ratio was 1.58 (95% confidence interval [CI] ϭ 1.15, 2.16). The median time to completion event in the placebo group was 17 days compared with 60 days in the combined azimilide group (Fig. 1) . The result of the primary efficacy analysis was consistent across subgroups (Fig. 2) ; that is, efficacy in none of the subgroups was significantly different from efficacy in the overall primary analysis.
When the loading period (day 1 to day 3) and the efficacy period were both included in the comparison of placebo (n ϭ 93) with the combined azimilide group (n ϭ 190), evidence of efficacy was comparable: chi-square 9.4, p ϭ 0.002; hazard ratio 1.61 (95% CI ϭ 1.19, 2.19). There appeared to be a very small, but favorable, effect of azimilide during the loading period; 19.3% of placebo patients had None of the subgroups demonstrated efficacy that was significantly different from the overall primary efficacy analysis. CHF ϭ congestive heart failure; HD ϭ heart disease; SHD ϭ structural heart disease. JACC Vol. 36, No. 3, 2000 Azimilide in Atrial Fibrillation
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The mean heart rates shown on the ECGs recorded at the time of completion events were 123.1 beats per min in the placebo group compared with 113.1 beats per min in the azimilide 50 mg QD group (p ϭ 0.04), 112.9 in the 100 mg QD group (p ϭ 0.06) and 113.6 in the 125 mg QD group (p ϭ 0.08). For the comparison of groups used in the primary efficacy analysis (combined azimilide 100 mg and 125 mg dose group with placebo, as specified in the protocol), the heart rate on azimilide was significantly slower (123.1 beats/min vs. 113.2 beats/min, p ϭ 0.04).
Asymptomatic atrial fibrillation and atrial flutter were occasionally recorded by transtelephonic ECG monitoring at the time of the biweekly routine contacts. These asymptomatic rhythms were recorded from 9.2% of patients in the placebo group compared with 8.1% of the azimilide 50 mg QD group, 4.3% of the 100 mg dose group and 4.4% of the 125 mg dose group (p Ͼ 0.20 for all comparisons vs. placebo). Safety. The variables analyzed to assess safety in all randomized patients included deaths, episodes of torsade de pointes and withdrawals due to adverse events. There were no deaths in the placebo group or the azimilide 100 mg dose group; there were two deaths in the azimilide 50 mg dose group and one in the 125 mg group. One of the deaths in patients receiving azimilide 50 mg QD was a 71-year-old woman who died of a stroke 29 days after beginning randomized therapy and 21 days after discontinuing randomized therapy. The other death in a patient receiving azimilide 50 mg QD was unobserved, presumed sudden death 35 days after randomization. This patient was a 61-year-old man with diabetes and a history of myocardial infarction and exercise-induced angina. The death in a patient receiving azimilide 125 mg QD was a 70-year-old man with a history of coronary artery disease, bypass grafting, heart failure, stroke, transient ischemic attacks and carotid endarterectomy two weeks before randomization. This patient had unwitnessed and presumed sudden death eight days after randomization.
One patient in the 100 mg dose group, an 86-year-old woman, had torsade de pointes on day 4 of blinded therapy while she was in atrial flutter with 2.72 s pauses. She recovered and discontinued protocol therapy.
The QTc measured on day 4 was compared with the baseline QTc and showed a mean (Ϯ standard deviation) change of ϩ1.0% (Ϯ6.6%), ϩ5.3% (Ϯ8.2%), ϩ6.2% (Ϯ8.3%), ϩ8.5% (Ϯ9.1%) in the placebo, 50 mg, 100 mg and 125 mg azimilide groups, respectively. Seven patients were required to withdraw for QTc Ͼ525 on ECGs recorded 4 to 187 days after randomization. One of these patients was receiving azimilide 50 mg QD, three were receiving 100 mg QD, and three were receiving 125 mg QD. In addition, withdrawal from the study due to an adverse event occurred in 0, 4, 2 and 2 patients in the placebo, 50 mg, 100 mg and 125 mg dose groups, respectively. The four patients who withdrew from the azimilide 50 mg group had (one each) a skin rash, abnormal liver function tests, diarrhea and a flu-like illness with weakness, dizziness and paresthesias. Two patients withdrew from the 100 mg dose group for (one each) dizziness and syncope. The latter patient was also taking the antiarrhythmic drug disopyramide, a protocol violation; an explanation for the syncope was not found. The two patients who withdrew from the 125 mg dose group had nonsustained ventricular tachycardia during hypokalemia (one patient) and premature ventricular beats (one patient).
DISCUSSION
Efficacy of azimilide. This randomized clinical trial demonstrated that azimilide is an effective antiarrhythmic drug 798 Pritchett et al. JACC Vol. 36, No. 3, 2000 Azimilide in Atrial Fibrillation September 2000 to reduce the frequency of symptomatic arrhythmia recurrences in patients with AF, atrial flutter or both, and it demonstrated the effective dose range for azimilide. In the primary efficacy analysis, the combined azimilide 100 mg and 125 mg dose group was significantly better than placebo (p ϭ 0.005). The hazard ratio for this comparison was 1.58 (95% CI ϭ 1.15, 2.16), and the median time to first symptomatic arrhythmia recurrence was lengthened from 17 days in the placebo group to 60 days in the combined azimilide group. The analysis of individual doses defined the effective dose range for azimilide. The 50 mg QD dose showed no relevant treatment effect while the 100 mg and 125 mg QD doses both showed clinically important effects.
An event committee reviewed all ECGs from symptomatic events and classified completion events as most consistent with either AF, atrial flutter or paroxysmal supraventricular tachycardia, and AF was the rhythm recorded during completion events in the vast majority of patients in all treatment groups. Importantly, higher doses of azimilide did not appear to increase the occurrence of atrial flutter compared with AF as has been reported with some other antiarrhythmic drugs (4) . There was a modest decrease in heart rate during completion events when the combined azimilide 100 mg and 125 mg group was compared with the placebo group. This decrease in heart rate, however, was not accompanied by evidence of an increase in the occurrence of asymptomatic arrhythmias detected by routine biweekly monitoring (5) . In fact, asymptomatic arrhythmias appeared to decrease slightly or higher doses of azimilide although the decrease was not statistically significant. It is not known, of course, whether asymptomatic AF is associated with any important adverse patient outcome, nor is it known whether treating asymptomatic AF with an antiarrhythmic drug is associated with beneficial effects. The effect of antiarrhythmic therapy on asymptomatic arrhythmias, however, warrants further study. Safety. More than 90% of patients began randomized therapy with azimilide as an outpatient, and azimilide was well tolerated. Torsade de pointes occurred in only one patient in this study. Three deaths occurred during the study. All occurred in patients with coronary artery disease, and all were thought to have a cardiovascular cause. Two of the deaths were in patients receiving azimilide 50 mg QD, the lowest dose tested and a dose not associated with clinical efficacy. An efficacy study of this size with only three deaths among 384 randomized patients is insufficient to establish the presence or absence of an effect of azimilide on mortality.
Patient withdrawals due to adverse events occurred infrequently and did not appear to increase with the higher doses tested. A precise estimate, however, of the rate at which these events occur in patients taking azimilide will require studying more patients. Trial design. This randomized trial included some novel features. Simple inclusion and exclusion criteria were designed to enroll a study population that was representative of many patients with AF and atrial flutter who are prescribed antiarrhythmic drug therapy; patients with all types of AF were included rather than limiting the trial to a single classification such as "paroxysmal" or "chronic" as has been done in many previous trials (6 -10) . The patients' arrhythmia histories demonstrated the frequent prior occurrence of multiple arrhythmias in these patients. Azimilide predominantly was begun in an outpatient setting, and no dose titration was used for patients receiving higher doses. Transtelephonic ECG monitoring provided objective documentation of the rhythm at the time of symptoms, and event committee review of all symptomatic ECGs assured a uniform standard for interpretation of these ECGs. Conclusions. Azimilide may be a promising new antiarrhythmic drug, but additional data on both efficacy and safety are required to establish its role in clinical practice. In this randomized clinical trial, azimilide was initiated in an outpatient setting, was administered once daily, did not require dose titration, showed promising efficacy and was well tolerated.
